Compare Continuation of Original Targeted Therapy With Trastuzumab Combined With Pyrotinib and Capecitabine as Postoperative Adjuvant Therapy in Non-pCR Patients With HER2 Positive Early Breast Cancer

To evaluate the efficacy of continuation targeted therapy compared with trastuzumab combined with Pyrotinib and capecitabine in postoperative adjuvant therapy of HER-2 positive early breast cancer patients with residual tumor (primary breast tumor/axillary lymph nodes) who did not achieve pCR after neoadjuvant therapy

Trial Details

NCT ID

NCT05292742

Phase

PHASE2

Sponsor

Fujian Medical University Union Hospital

Status

RECRUITING

Cancer Type

Breast Cancer

Interventions

Pyrotinib+Trastuzumab+Capecitabine
Trastuzumab+Pertuzumab/Trastuzumab

Locations (sample)

Fuzhou, Fujian, China|26.06139,119.30611

Key Eligibility Criteria

Female patients aged ≥ 18 years and ≤ 75 years old with primary breast cancer
ECOG score 0 \~ 1
Breast cancer meets the following criteria: 1）Histologically or pathologically confirmed invasive breast cancer, primary tumor stage determined by …
Primary breast cancer lesion or lymph node invasive cancer confirmed by pathology after neoadjuvant therapy (residual invasive breast cancer lesion…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →